睿知中国疾病研究地图
候选清单0

即将招募胃癌IV期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由西安交通大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06499610,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with pathologically confirmed advanced gastric cancer and adenocarcinoma of the gastroesophageal junction;

    入选标准第 4 条

    Consent to provide the histological samples;

    入选标准第 12 条

  3. The ECOG score is 0-2 points;

    入选标准第 9 条

  4. Bone marrow function: neutrophils 1.5109 / L, platelets 100109 / L, and hemoglobin 75g / L;

    入选标准第 8 条

    Liver and kidney function: upper limit of 1.5 times normal value of serum creatinine; upper limit of normal value of AST and ALT (upper limit of normal value of 5 times for patients with liver invasion); upper limit of normal value of total bilirubin (upper limit of normal value of 3 times for patients with liver invasion);

    入选标准第 10 条

  5. According to RECIST1.1 criteria, the patient has at least one measurable diameter target lesion (long diameter of tumor lesion CT scan 10mm, short diameter of lymph node lesion CT scan 15mm and scanning layer thickness of 5mm);

    入选标准第 7 条

  6. According to the HER 2 testing process and evaluation criteria in CSCO Guidelines for Diagnosis and Treatment of Gastric Cancer 2024 edition: confirmed by immunohistochemistry (IHC), HER2 2 + accompanied by in situ hybridization with gene amplification or HER2 3 +;

    排除标准第 6 条

    Active infection of hepatitis B and C (positive for HBV surface antigen and 1x103 copies / mL and 1x103 copies / mL);

    排除标准第 16 条

    Human immunodeficiency virus (HIV) infection (HIV antibody positive);

    排除标准第 17 条

  7. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraception;

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06499610,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The patient was fully aware of the study and volunteered to participate in and signed the informed consent form (ICF);
  2. Age≥18 years old;
  3. Expected survival time of 3 months;
  4. Patients with pathologically confirmed advanced gastric cancer and adenocarcinoma of the gastroesophageal junction;
  5. Failure or intolerance of previous first-line anti-tumor therapy;
  6. CPS 1 was detected by PD-L1 expression level;
  7. According to RECIST1.1 criteria, the patient has at least one measurable diameter target lesion (long diameter of tumor lesion CT scan 10mm, short diameter of lymph node lesion CT scan 15mm and scanning layer thickness of 5mm);
  8. Bone marrow function: neutrophils 1.5109 / L, platelets 100109 / L, and hemoglobin 75g / L;
  9. The ECOG score is 0-2 points;
  10. Liver and kidney function: upper limit of 1.5 times normal value of serum creatinine; upper limit of normal value of AST and ALT (upper limit of normal value of 5 times for patients with liver invasion); upper limit of normal value of total bilirubin (upper limit of normal value of 3 times for patients with liver invasion);
  11. Women of childbearing age must have a negative pregnancy test (serum) within 7 days before enrollment, and must be willing to use appropriate methods for contraception during the trial;
  12. Consent to provide the histological samples;

排除标准:Exclusion Criteria:

  1. Allergic reaction to any study drug or its ingredients;
  2. Patients with severe hepatic and renal insufficiency;
  3. Have used a strong CYP3A4 inducer within 2 weeks before the first dose of the trial drug, or have used a strong CYP3A4 inhibitor or a strong UGT1A1 inhibitor within 1 week;
  4. Uncontrollable systemic diseases (such as advanced infection, uncontrolled hypertension, diabetes mellitus, etc.);
  5. Patients with intestinal obstruction and gastrointestinal bleeding;
  6. According to the HER 2 testing process and evaluation criteria in CSCO Guidelines for Diagnosis and Treatment of Gastric Cancer 2024 edition: confirmed by immunohistochemistry (IHC), HER2 2 + accompanied by in situ hybridization with gene amplification or HER2 3 +;
  7. Have any active autoimmune disease or a history of autoimmune disease, such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, and reduced thyroid function (which can be included after normal hormone replacement therapy);
  8. Heart function and disease are one of the following:
  9. Long QTc syndrome or QTc interval> 480 ms;
  10. Complete left bundle branch block, degree II or III atrioventricular block;
  11. Severe, uncontrolled arrhythmias requiring medical therapy;
  12. New York Society of Cardiology grade III;
  13. Cardiac ejection fraction (LVEF) below 50%;
  14. history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinically severe pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.
  15. Uncontrolled ascites and abdominal cavity infection;
  16. Active infection of hepatitis B and C (positive for HBV surface antigen and 1x103 copies / mL and 1x103 copies / mL);
  17. Human immunodeficiency virus (HIV) infection (HIV antibody positive);
  18. Previous or current other malignancies (except basal cell carcinoma of the skin with non-melanoma, carcinoma of the breast / cervix in situ, and other malignancies that have been effectively controlled without treatment in the past five years);
  19. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraception;
  20. Other investigator judged ineligible for this study.

引自 ClinicalTrials.gov, NCT06499610, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06499610,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06499610